Cannabidiol: 12 agencies, 2015–2026
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
PBAC (Australia) has been harder on cannabidiol than on its own caseload: it refused 3 of 6 decisive submissions here (50%), against a base rate of 24% across everything it has assessed.
Assessment has run over 10.9 years, from 13 Aug 2015 at PHARMAC (New Zealand) to 2026 at PBAC (Australia).
TLV (Sweden) changed its position: not recommended on 29 Sep 2020, restricted by 26 May 2026, after a resubmission.
No assessment is on file from CIPM (Spain), which is among the eight highest-volume agencies here.
The file is active: 12 of 35 records date from 2023 or later.
The programme is broad: 11 distinct indication wordings are recorded for cannabidiol by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
7 of these 35 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
PHARMAC (New Zealand) was first to assess cannabidiol, on 13 Aug 2015; G-BA (Germany) did not open a file until 16 May 2024 — an unusually long tail of 8.8 years between the earliest and latest system to look at it.
The record arrives in waves: 8 separate years each carry two or more decisions, spread across 9 years in total.
Restriction is doing real work here: 7 of 28 decisive outcomes narrowed cannabidiol to a subgroup rather than accepting or refusing it outright, at AIFA (Italy), AOTMIT (Poland) and NICE (England) among others.
12 of the 12 agencies here assessed cannabidiol more than once, PBAC (Australia) most often at 7 entries — repeat review is the norm for this molecule rather than the exception.
cannabidiol has been through 12 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for cannabidiol reads 14 recommended, 7 restricted, 7 not recommended and 3 no benefit, with 4 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| TLV (Sweden) | 26 May 2026 | Epidyolex ingår i högkostnadsskyddet med begränsning | restricted subsidy | source |
| PBAC (Australia) | 2025 | Seizures of the Lennox-Gastaut syndrome (LGS) | Recommended | source |
| ZIN (Netherlands) | 24 Feb 2025 | Advies - vergoed cannabidiol (Epidyolex®) voor de behandeling van de ziekte van Bourneville-Pringle | advice published | source |
| G-BA (Germany) | 16 May 2024 | Epidyolex — benefit assessment §35a | added benefit: not proven | source |
| AOTMIT (Poland) | 8 Oct 2021 | Epidyolex reimbursement recommendation | not recommended | source |
30 further decisions for cannabidiol, across 12 agencies, are not shown here. They include the most recent record on file, 2026 from PBAC (Australia); its outcome is in the subscriber dataset. They link to 22 further source documents.
Related molecules
- levetiracetam — same ATC class N03A — Antiepileptics
- perampanel — same ATC class N03A — Antiepileptics
- lacosamide — same ATC class N03A — Antiepileptics
- brivaracetam — same ATC class N03A — Antiepileptics
- zonisamide — same ATC class N03A — Antiepileptics
- rufinamide — same ATC class N03A — Antiepileptics
Coverage: 35 decisions for cannabidiol from 12 agencies, 2015 to 2026. Data to 7 Sep 2026. ATC class N03A — Antiepileptics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.